Solid Biosciences (SLDB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.38
- Estimate
- -$0.47
- Surprise
- +18.6%
- Score today
- 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Solid Biosciences (SLDB) reported a narrower loss than forecast — diluted EPS of -$0.38 against the -$0.47 estimate (a 18.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SLDB Sell at 5.7/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +18.6% surprise compares with a +5.7% four-quarter average. Next scheduled report: 2026-11-02.
What argues against it
- Concentration risk — Pipeline: SGT-003
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.86
- Price target
- $16.24
- Stop
- $8.11
- Upside to target
- +83.3%
- Reward-to-risk
- 7.4:1
Risk check: trading volume is running 2.3× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
SLDB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $897.5M
- P/E (fwd)
- -4.8
- 52-week range
- $3.79–$11.45
- Off 52-week high
- 22.6%
- RSI (14)
- 38
- Volume vs avg
- 2.34×
- Score today
- 5.7/10